Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 537-537 ◽  
Author(s):  
M. Dowsett ◽  
I. E. Smith
2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17523-e17523
Author(s):  
H. Pfaff ◽  
P. Steffen ◽  
A. Nitzsche ◽  
C. Kowalski

e17523 Background: The purpose of this study is to investigate the impact of organizational characteristics of the hospital on general health perception in postoperative primary breast cancer patients after discharge from hospital. Methods: Patients undergoing treatment for primary breast cancer in all certified breast centers in North Rhine-Westphalia (Germany) were invited to self-administer a questionnaire on health-related quality of life after discharge. Survey period was February to July 2007. 3,285 patients from 94 hospitals returned the questionnaire. The data were supplemented by disease and treatment characteristics reported by the oncologists (e.g. TNM-classification, type of surgery). Patient data were combined with information on hospital characteristics provided by hospital administrators. A multilevel analysis was applied to analyse the impact of organizational characteristics of the hospital (no. of annual breast cancer surgeries, breast care nurses employed, teaching hospital) on general health perception as reported by the breast cancer patients after discharge. Analyses were controlled for sociodemographic variables (age, marital status, education), type of surgery (mastectomy vs. BCT), and severity of disease (TNM-classification). Results: In the multilevel analysis performed organizational characteristics of the hospital do not contribute to patients’ general health after discharge. Only the variable “breast care nurses employed” is close to being positively associated with better general health at p < 0.05. In the model lymph node status (p < 0.05), metastases (p < 0.05), type of surgery (p < 0.01), age (p < 0.001), and education (p < 0.01) contribute to the explanation of the variance in general health perception. Conclusions: In the breast centers under investigation organizational characteristics of the hospital do not have an impact on primary breast cancer patients’ general health after hospital discharge. A possible reason is the high degree to which the treatment process itself is standardized. No significant financial relationships to disclose.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e14146-e14146
Author(s):  
Tesia McKenzie ◽  
Davina Matinho ◽  
Olivia Scott ◽  
Arbaz Khan ◽  
Mila Lachica ◽  
...  

e14146 Background: Breast cancer (BC) is the most common invasive cancer in adult females.The role of preoperative MRI in assessing the extent of primary breast cancer remains controversial. This study’s objective is to determine if MRIs performed after the diagnosis of invasive/non-invasive-breast cancer will identify additional breast cancers. We hypothesize that preoperative MRIs will result in the discovery of additional significant lesions, leading to changes in surgical treatment. Methods: A retrospective study of 389 BC patient charts were reviewed, dated from January 2000- July 2019. Files were collected from an office in the Breast Cancer Surgery Department. Information on each patient’s imaging studies, treatment, demographics, surgery, and pathology were collected and stored in anonline cloud system. Summary statistics, including proportions, percentages, and difference of proportion hypothesis tests were utilized to interpret the data. All statistical tests were conducted at a 95% confidence interval. Results: We reviewed the charts of 335 patients that met eligibility criteria. In 221 newly diagnosed cancers, a preoperative MRI was taken before treatment. 127 cancers (57.5%)showed additional finding.In BC patients with additional preoperative MRI findings, we observed 61.4%true positive and 38.6%false positive results. These values are comparable to prior studies.We determined that the treatment plan was altered in 17.6%of all patients who received an MRI and in 30.7%of patients with a true positive MRI finding, which is also consistent with previous literature.A majority of the treatment changes were from Lumpectomy to Mastectomy. Conclusions: Literature on MRI use in BC diagnosis exists; our study differs by focusing on newly diagnosed breast cancers.We discovered 35.3% of preoperative MRIs identified a true additional finding in known breast cancer. In addition, our true positive rate (61.4%) and false positive rate (22.2%) of MRI findings is comparable to those of previous studies. Plans were changed in 30.7% of additional findings supporting the idea that preoperative MRI studies are useful when organizing surgical treatment. Further studies to demonstrate the impact on local recurrence rates and overall survival, may clarify the true role of pre-operative MRI in these cases.


Cancers ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 140
Author(s):  
Renaud Sabatier ◽  
Jean-Yves Pierga ◽  
Hervé Curé ◽  
Rakan Abulnaja ◽  
Eric Lambaudie ◽  
...  

The phase II AVASTEM trial explored the impact of chemotherapy-bevacizumab combination on breast cancer stem cells in the neoadjuvant setting. We aimed to identify biological features associated with preoperative chemotherapy efficacy and prognosis by analyses of circulating tumor cells (CTCs) and bevacizumab pharmacokinetics (PK). The main objective was to assess the prognostic (relapse-free survival and overall survival) and predictive (pathological complete response, pCR) values of CTCs (CellSearch technology) and bevacizumab PK (ELISA). Seventy-five patients were included. Out of them 50 received bevacizumab-chemotherapy and 25 received chemotherapy alone. CTC results were available for 60 patients and PK data for 29 patients in the experimental arm. The absence of CTC at inclusion was correlated to better outcome. Five-years overall survival (OS) was 91% for CTC-negative patients vs. 54% for CTC-positive cases (HR = 6.21; 95%CI (1.75–22.06), p = 0.001, log-rank test). Similar results were observed for RFS with 5 y-RFS of 78% vs. 44% (HR = 3.51; 95%CI (1.17–10.52), p = 0.017, log-rank test). However, CTC status at baseline was not predictive of pCR (p = 0.74). CTC status after one cycle was not a significant prognostic factor (HR = 1.56; 95%CI (0.19–12.67); p = 0.68 for OS and HR = 2.76; 95%CI (0.60–12.61); p = 0.17 for RFS, log-rank test). Bevacizumab serum levels could not predict pCR and survival. PK values were not associated with treatment-related toxicities. In conclusion, CTCs detection at baseline is a prognostic marker for breast cancer receiving a neoadjuvant chemotherapy-bevacizumab combination independently of tumor response.


Sign in / Sign up

Export Citation Format

Share Document